49 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
25599836	14	Multi-parameter optimization of aza-follow-ups to BI 207524, a thumb pocket 1 HCV NS5B polymerase inhibitor. Part 2: Impact of lipophilicity on promiscuity and in vivo toxicity.	Boehringer Ingelheim (Canada)
25650311	76	Synthesis and pharmacological characterization of 2-aminobenzaldehyde oxime analogs as dual inhibitors of neutrophil elastase and proteinase 3.	Chang Gung University
24524217	65	Structurally novel highly potent proteasome inhibitors created by the structure-based hybridization of nonpeptidic belactosin derivatives and peptide boronates.	Hokkaido University
24224573	31	Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors.	Universidade De Lisboa
23719288	41	Discovery of novel series of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as human chymase inhibitors using structure-based drug design.	Asubio Pharma
23659209	30	Discovery of potent, selective chymase inhibitors via fragment linking strategies.	Boehringer Ingelheim Pharmaceuticals
16644215	52	Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.	Celera Genomics
22882079	26	Synthesis and evaluation of silanediols as highly selective uncompetitive inhibitors of human neutrophil elastase.	Aarhus University
22595175	18	N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases.	University Of Lisbon
18995931	16	Natural polyprenylated benzophenones inhibiting cysteine and serine proteases.	Federal University Of Alfenas
17535802	91	Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.	Merck Research Laboratories
18247547	6	Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer.	Cephalon
12190311	37	Discovery of further pyrrolidine trans-lactams as inhibitors of human neutrophil elastase (HNE) with potential as development candidates and the crystal structure of HNE complexed with an inhibitor (GW475151).	Gsk
11312928	62	Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic difluoromethylene ketones as novel inhibitors of human chymase.	Welfide
11312927	64	Synthesis, structure-activity relationships, and pharmacokinetic profiles of nonpeptidic alpha-keto heterocycles as novel inhibitors of human chymase.	Welfide
1578486	53	Novel anthraquinone inhibitors of human leukocyte elastase and cathepsin G.	Georgia Institute Of Technology
21733690	40	Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region.	Boehringer Ingelheim Pharmaceuticals
20925433	21	Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.	Aristotle University Of Thessaloniki
19483697	23	Phage-encoded combinatorial chemical libraries based on bicyclic peptides.	Laboratory Of Molecular Biology, Medical Research Council
20102150	35	Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif.	Johnson & Johnson Pharmaceutical Research And Development
19665376	48	Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C.	Merck Frosst Canada
19908842	84	Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.	National Human Genome Research Institute
	7	Janus compounds: dual inhibitors of proteinases	TBA
19362846	1	Introduction of non-natural amino acid residues into the substrate-specific P1 position of trypsin inhibitor SFTI-1 yields potent chymotrypsin and cathepsin G inhibitors.	University Of Gda£?Sk
18701300	55	Synthesis and elastase-inhibiting activity of 2-pyridinyl-isothiazol-3(2H)-one 1,1-dioxides.	University Of Leipzig
17434735	34	Development of 6-benzyl substituted 4-aminocarbonyl-1,4-diazepane-2,5-diones as orally active human chymase inhibitors.	Daiichi Asubio Pharma
17419055	30	Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors.	Daiichi Asubio Pharma
17361995	31	Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase.	Johnson & Johnson Pharmaceutical Research And Development
14761180	31	Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G.	Johnson & Johnson Pharmaceutical Research & Development
14592513	24	Structure-activity relationship of benzo[b]thiophene-2-sulfonamide derivatives as novel human chymase inhibitors.	Toa Eiyo
11425539	23	Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones.	Shionogi
11078188	20	1-Oxacephem-based human chymase inhibitors: discovery of stable inhibitors in human plasma.	Shionogi
11078187	36	Synthesis and structure-activity relationships of a new class of 1-oxacephem-based human chymase inhibitors.	Shionogi
10698435	150	Structure-activity relationship studies of chloromethyl ketone derivatives for selective human chymase inhibitors.	Kyoto Pharmaceutical University
10091694	90	Symmetrical anhydride-type serine protease inhibitors: structure-activity relationship studies of human chymase inhibitors.	Nippon Steel
9925737	57	N-[2,2-dimethyl-3-(N-(4-cyanobenzoyl)amino)nonanoyl]-L-phenylalanine ethyl ester as a stable ester-type inhibitor of chymotrypsin-like serine proteases: structural requirements for potent inhibition of alpha-chymotrypsin.	Nippon Steel
9871680	5	Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids.	Proscript
9767628	31	Syntheses of trans-5-oxo-hexahydro-pyrrolo[3,2-b]pyrroles and trans-5-oxo-hexahydro-furo[3,2-b]pyrroles (pyrrolidine trans-lactams and trans-lactones): new pharmacophores for elastase inhibition.	Glaxowellcome Medicines Research Centre
9379436	46	Orally active trifluoromethyl ketone inhibitors of human leukocyte elastase.	Zeneca Pharmaceuticals
9341916	30	Anionic- and lipophilic-mediated surface binding inhibitors of human leukocyte elastase.	RhôNe-Poulenc Rorer
9216834	153	Substituted 3-(phenylsulfonyl)-1-phenylimidazolidine-2,4-dione derivatives as novel nonpeptide inhibitors of human heart chymase.	Suntory
7837244	33	Non-peptidic inhibitors of human leukocyte elastase. 4. Design, synthesis, and in vitro and in vivo activity of a series of beta-carbolinone-containing trifluoromethyl ketones.	Zeneca Pharmaceuticals
7739010	118	Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin.	Thrombosis Research Institute
7629790	32	New orally active serine protease inhibitors.	Minase Research Institute
7562931	41	Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles.	Zeneca Pharmaceuticals
2296031	48	Synthesis of peptidyl fluoromethyl ketones and peptidyl alpha-keto esters as inhibitors of porcine pancreatic elastase, human neutrophil elastase, and rat and human neutrophil cathepsin G.	Merrell Dow Research Institute
10715152	151	5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: potent nonpeptidic inhibitors of HIV protease.	Parke-Davis Pharmaceutical Research